Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy approaches for osteogenesis imperfecta.

C Niyibizi1, S Wang, Z Mi

  • 1Department of Orthopaedic Surgery, Ferguson Laboratories for Orthopaedic Research, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. cniyibizi@psu.edu

Gene Therapy
|January 16, 2004
PubMed
Summary

Osteogenesis imperfecta (OI) is a genetic disorder causing bone fragility due to collagen mutations. Current treatments focus on managing symptoms, while cell and gene therapies are being explored for future OI management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exosomes in the Pathogenesis, Diagnosis and Treatment of Pancreatic Diseases.

CellR4-- repair, replacement, regeneration, & reprogramming·2021
Same author

Age-dependent changes in intervertebral disc cell mitochondria and bioenergetics.

European cells & materials·2018
Same author

Exosomes as biomarkers and therapeutic tools for type 1 diabetes mellitus.

European review for medical and pharmacological sciences·2017
Same author

Possibilities of gene therapy in traumatic and degenerative lesions of the joints. Current experimental status and preliminary clinical applications.

Der Orthopade·2017
Same author

NF-κB inhibition reveals a novel role for HGF during skeletal muscle repair.

Cell death & disease·2015
Same author

Renal cell carcinoma to haemangioblastoma metastasis: a rare manifestation of Von Hippel-Lindau syndrome.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2014

Area of Science:

  • Genetics
  • Biochemistry
  • Orthopedics

Background:

  • Osteogenesis imperfecta (OI) is a group of genetic disorders characterized by impaired connective tissue integrity and bone fragility.
  • Manifestations range from mild osteopenia to severe skeletal deformities and prenatal lethality.
  • Most OI cases stem from mutations in genes encoding type I collagen polypeptide chains.

Purpose of the Study:

  • To review the molecular basis of Osteogenesis imperfecta (OI).
  • To discuss current therapeutic strategies for OI.
  • To explore emerging cell and gene therapy approaches for OI treatment.

Main Methods:

  • Literature review of genetic disorders affecting connective tissue.
  • Analysis of current clinical interventions for bone fragility.

Related Experiment Videos

  • Evaluation of ongoing research in cell and gene therapies for OI.

    • Main Results:

    • OI is primarily caused by mutations in type I collagen genes, leading to bone fragility.
    • Current treatments include surgical stabilization and bisphosphonates, with limited success in altering disease course.
    • Gene therapy development is challenged by OI's genetic heterogeneity and dominant-negative mutation mechanisms.

    Conclusions:

    • Effective OI management requires addressing symptom severity and maximizing function.
    • Novel therapeutic strategies, including cell and gene therapies, are crucial for future OI treatment.
    • Understanding molecular defects is key to developing targeted OI therapies.